KẾT QUẢ ĐIỀU TRỊ BẰNG PHÁC ĐỒ CÓ PHỐI HỢP THUỐC DAPAGLIFLOZIN Ở BỆNH NHÂN SUY TIM CÓ PHÂN SUẤT TỐNG MÁU THẤT TRÁI GIẢM TẠI BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN

Abstract

Fifty-five patients were treated for heart failure at Thai Nguyen National Hospital between July 1, 2023, and August 31, 2024. Objective: To describe the clinical and subclinical characteristics and treatment outcomes of Dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction. Results: Male patients accounted for a higher proportion, with a male-to-female ratio of 2:1. Among patients with prior medical histories, hypertension was the most common at 87.3%, arrhythmias were present in 43.6%, and 29.1% of patients had diabetes. NYHA functional classification was as follows: NYHA II - 20%, NYHA III - 69.1%, and NYHA IV - 10.9%. Changes in heart rate and blood pressure were not statistically significant (p < 0.05). The ejection fraction (EF) before treatment was 28.72±9.04%, and after treatment, it improved to 40.1±11.65%. Atrial fibrillation was observed in 41.8% of patients, and ventricular extrasystoles in 14.5%. Chest X-rays showed pulmonary congestion in 49.1% of patients, and 85.5% of patients had cardiomegaly. Patients receiving treatment with four types of medication accounted for 58.2%.